SCYNEXIS Announces Transformative Acquisition of PXL-770 (SCY-770) for the Treatment of ADPKD

Key Highlights for Investors

• Acquisition of PXL-770 (now SCY-770): SCYNEXIS, Inc. (NASDAQ: SCYX) has entered into a definitive agreement with Poxel S.A. to acquire PXL-770, a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator. This oral therapy is being developed for Autosomal Dominant Polycystic Kidney Disease (ADPKD), the leading genetic cause of end-stage renal failure.
• Clinical Development Plans: SCYNEXIS expects to initiate a Phase 2 proof-of-concept (POC) study in ADPKD patients in Q4 2026, with an early efficacy readout anticipated in the second half of 2027.
• Regulatory Advantage: SCY-770 has received Orphan Drug Designation from the U.S. FDA, which confers potential regulatory and commercial incentives.
• Strong Preclinical and Clinical Data: SCY-770 has been evaluated in eight clinical trials (including Phase 1 and a Phase 2a in NAFLD), demonstrating a favorable safety profile and compelling preclinical activity supporting its utility in ADPKD.
• Substantial Market Opportunity: ADPKD affects approximately 140,000 patients in the U.S., with 6,000 new diagnoses annually. The only currently approved therapy, Jynarque (tolvaptan), achieved approximately \$1.5 billion in U.S. sales in 2024 despite uptake challenges, highlighting the significant unmet need.
• Acquisition Terms: SCYNEXIS will make an upfront payment of \$8 million, with up to \$8 million in development milestones and up to \$180 million in commercial milestones (of which \$125 million is triggered by annual net sales at or above \$1 billion).
• Shareholder Value Creation: Management views this acquisition as a major step in expanding the company’s pipeline targeting severe and rare diseases, which could unlock significant value for shareholders.
• Conference Call: SCYNEXIS will host a live conference call on March 31, 2026, at 8:30 a.m. ET to discuss the acquisition and provide a corporate update. Dial-in details are available for interested stakeholders.

Key Details and Rationale

SCYNEXIS’s acquisition of SCY-770 brings a novel, differentiated mechanism of action (MOA) to the ADPKD market. As a direct AMPK activator, SCY-770 is designed to target multiple drivers of ADPKD progression, including reducing cyst growth and slowing disease progression. The company’s leadership emphasized SCY-770’s strong preclinical package and clinical safety data, positioning it as a leading candidate in a rare disease market with high unmet need and limited therapeutic options.

ADPKD patients endure a lifelong disease burden, often necessitating renal replacement therapy. The only FDA-approved treatment, Jynarque (tolvaptan), has safety and tolerability issues, restricting patient uptake. The entry of SCY-770 into clinical development, with the potential for improved safety and efficacy, could represent a major shift in the standard of care and open a multibillion-dollar market for SCYNEXIS.

Financial and Strategic Impact

• Milestone Payments: The acquisition structure aligns the majority of payments with successful commercial performance, minimizing upfront risk and maximizing shareholder alignment.
• Pipeline Synergy: This acquisition complements SCYNEXIS’s existing antifungal portfolio (including BREXAFEMME, partnered with GSK, and SCY-247 in Phase 1), solidifying the company’s focus on severe and rare diseases.
• Potential Share Price Impact: The acquisition of SCY-770, with Orphan Drug Designation and a clear clinical development path, is a potentially significant catalyst for SCYNEXIS shares, especially as the only other approved ADPKD therapy has generated substantial U.S. sales despite limitations.

Additional Notes

• SCYNEXIS has previously outlicensed BREXAFEMME to GSK and may receive up to \$146 million in annual net sales milestones plus royalties.
• The company continues to develop its antifungal pipeline and seek non-dilutive funding opportunities, with SCY-247 in a Phase 1 IV formulation trial and other assets in pre-clinical stages.
• Forward-looking statements in the company’s release emphasize that actual results may differ due to regulatory, clinical, and market risks.

Conclusion

The acquisition of SCY-770 is a transformative event for SCYNEXIS, potentially driving significant value creation for shareholders. The entry into the ADPKD market with a novel mechanism, the potential for commercial milestones, and the strengthening of the company’s position in rare diseases are all highly material developments that could positively affect share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties as detailed in SCYNEXIS’s filings with the SEC.

View SCYNEXIS INC Historical chart here